Clinical trials: Amlodipine
Hypertension
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
Recruiting in Germany only: This study will evaluate the safety and efficacy of valsartan plus HCTZ in fixed dose combination in hypertensive patients not responding to treatment with the free combination of Candesartan plus…
- Trial name
- NCT00360178
- Testing
- Valsartan plus Hydrochlorothiazide, Candesartan plus Hydrochlorothiazide, Amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 198 people
- Sponsor
- Novartis
Hypertension
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment
- Trial name
- NCT02620163
- Testing
- telmisartan/amlodipine 40/5mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine 80/5mg
- Where
- South Korea
- Volunteers
- 381 people
- Sponsor
- Yuhan Corporation
Hypertension
Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
This study will be conducted to assess the efficacy and safety of an amlodipine/olmesartan treatment regimen in stage 1 and stage 2 hypertensive subjects.
- Trial name
- NCT00527514
- Testing
- Amlodipine, Olmesartan medoxomil plus amlodipine
- Where
- 18 sites in United States
- Volunteers
- 185 people
- Sponsor
- Daiichi Sankyo
Essential Hypertension ( Mild to Moderate)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension.
- Trial name
- NCT00765947
- Testing
- Aliskiren, Hydrochlorothiazide, Amlodipine
- Where
- 4 sites in France, Hungary and 2 more
- Volunteers
- 256 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension
- Trial name
- NCT00171535
- Testing
- valsartan/amlodipine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Novartis
Hypertension
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
This study are (1) to assess the relative bioavailability (BA) of a single oral dose of either 5 mg of Levamlodipine Maleate Tablets from CSPC or 10 mg of Amlodipine Besylate Tablet (NORVASC®) from Pfizer Inc.
- Trial name
- NCT03657550
- Testing
- Levamlodipine, Amlodipine, Amlodipine, Levamlodipine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean…
- Trial name
- NCT00437645
- Testing
- Valsartan 160 mg capsules, Amlodipine 5 mg capsules
- Where
- 12 sites in Argentina, Chile and 10 more
- Volunteers
- 1,183 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
Study Design : A single center, open, randomized, single dose, two-period, two-treatment, two-sequence, crossover study
- Trial name
- NCT01197014
- Testing
- Amlodipine plus Losartan, Amlodipine, Losartan
- Where
- Czechia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Fed
Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions
The purpose of this study single dose bioequivalence of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules with Lotrel® capsules in healthy human subjects and monitor clinical status, adverse events and laboratory…
- Trial name
- NCT01505998
- Testing
- Amlodipine Besylate/Benazepril HCl
- Where
- India
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Hypertension, Diabetes Mellitus, Type 2
ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria
The purpose of the study is to compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®. The secondary objectives were listed as the following.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Albuminuria
- Trial name
- NCT01375322
- Testing
- Amlodipine+Benazepril, Valsartan+Hydrochlorothiazide
- Where
- 4 sites in Taiwan
- Volunteers
- 226 people
- Sponsor
- TSH Biopharm Corporation Limited
Essential Hypertension
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
- Trial name
- NCT01131546
- Testing
- Levamlodipine besylate, Amlodipine maleate
- Where
- China
- Volunteers
- 1,080 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Hypertension
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT03897868)
- Testing
- HCP1803, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
HYPERTENSION
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
A ONE YEAR SAFETY STUDY FOR PATIENTS WHO COMPLETE STUDY VAA489A2307.
- Trial name
- NCT00170976
- Testing
- valsartan + amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 403 people
- Sponsor
- Novartis
Hypertension
Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled
To Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine (Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy
- Trial name
- NCT02526875
- Testing
- Telminuvo®Tab. 40/2.5mg
- Where
- 10 sites in South Korea
- Volunteers
- 208 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
This observational study is designed to evaluate the effects of Twynsta tablets with life style modifications on blood pressure, quality of life, and other risk factors in Korean patients with hypertension in a routine clinical…
- Trial name
- NCT01316419
- Testing
- Telmisartan, amlodipine
- Where
- 55 sites in South Korea
- Volunteers
- 2,089 people
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects
This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate, valsartan and rosuvastatin in healthy male volunteers.
- Trial name
- NCT02060019
- Testing
- administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by amlodipine besylate monotherapy.
- Trial name
- NCT02368665
- Testing
- Amlodipine 5mg, Amlodipine 5mg, Candesartan cilexetil 16mg, Amlodipine 10mg, Candesartan cilexetil 16mg
- Where
- 19 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- HK inno.N Corporation
Hypertension
Filtered Trial for Telmisartan 40mg Non-responder
The primary purpose of this study is to: Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately…
- Trial name
- NCT00550953
- Testing
- telmisartan+amlodipine, telmisartan
- Where
- 5 sites in Japan
- Volunteers
- 314 people
- Sponsor
- Boehringer Ingelheim
Hypertension
AMISH : Aprovel for Management of Isolated Systolic Hypertension
To compare the antihypertensive efficacy and tolerability of irbesartan and irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus hydrochlorothiazide in the treatment of isolated systolic…
- Trial name
- NCT00264212
- Testing
- irbesartan and irbesartan-hydrochlorothiazide
- Where
- 8 sites in Chile, China and 6 more
- Volunteers
- 436 people
- Sponsor
- Sanofi
Hypertension
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in…
- Trial name
- NCT00553267
- Testing
- fixed dose combination of telmisartan+amlodipine, amlodipine
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 947 people
- Sponsor
- Boehringer Ingelheim